Company: MIRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024077
Chunk: 12

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 12
---
2024 Annual Report. The CEO assesses performance for the Company and decides how to allocate resources
based on the aggregate net loss that is also reported on the income statement as net loss. The measure of segment assets is reported
on the balance sheets as total assets.

The
table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

Schedule
of segment expenses and other segment expenses 

    2025  
    2024 

    Six
    Months Ended June 30, 

    2025  
    2024 
  
    Revenues 
    $—  
    $— 
  
    Less segment expenses: 

    Research and development 
     810,601  
     1,376,738 
  
    General and administrative 
     2,540,699  
     2,122,170 
  
    Loss from operations 
    $3,351,300  
     3,498,908 
  
    Plus: 

    Other income, net 
     29,809  
     89,812 
  
    Segment net loss 
    $(3,321,491) 
    $(3,409,096)

Note
7. Subsequent Events

ATM
Offering

On
July 3, 2025, MIRA Pharmaceuticals, Inc. (the “Company”), sold a total of 1,540,741 shares of its common stock, par value
$0.001, in block sales to an institutional investor, at an average price of $1.2981 share (a premium to the prior days close), through
its at-the-market equity offering facility (the “Offering”). Gross proceeds from the Offering totaled approximately $2.0
million, prior to deducting fees and expenses. The trades for the Offering were facilitated through Rodman & Renshaw, via the StockBlock
platform. The Offering did not include any warrants.

On
July 1, 2025, under the ATM Agreement, the Company sold and issued 17,373
shares of common stock at an average price per share of $1.3121
and received net proceeds of approximately $0.2
million after deducting commissions and other fees of $570.

Exercise of Options 

On July 15, 2025, Michelle Yanez, the
Company’s former Chief Financial Officer, exercised options to purchase 126,061 shares